Barclays PLC Raises Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Barclays PLC grew its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 70.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 66,728 shares of the specialty pharmaceutical company's stock after acquiring an additional 27,518 shares during the quarter. Barclays PLC owned about 0.11% of Jazz Pharmaceuticals worth $8,216,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Synovus Financial Corp lifted its position in Jazz Pharmaceuticals by 0.5% during the fourth quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company's stock valued at $2,365,000 after purchasing an additional 100 shares during the last quarter. Optimize Financial Inc bought a new position in Jazz Pharmaceuticals during the 4th quarter worth about $253,000. Townsquare Capital LLC raised its holdings in shares of Jazz Pharmaceuticals by 79.5% in the 4th quarter. Townsquare Capital LLC now owns 3,540 shares of the specialty pharmaceutical company's stock valued at $436,000 after purchasing an additional 1,568 shares in the last quarter. Rockefeller Capital Management L.P. boosted its stake in shares of Jazz Pharmaceuticals by 1.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 250,410 shares of the specialty pharmaceutical company's stock valued at $30,838,000 after purchasing an additional 4,006 shares in the last quarter. Finally, Sterling Capital Management LLC lifted its holdings in Jazz Pharmaceuticals by 9.0% during the fourth quarter. Sterling Capital Management LLC now owns 15,215 shares of the specialty pharmaceutical company's stock worth $1,874,000 after buying an additional 1,260 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock traded up $0.76 on Tuesday, reaching $113.65. 104,587 shares of the company were exchanged, compared to its average volume of 795,873. The business has a 50-day moving average price of $124.20 and a 200 day moving average price of $122.44. Jazz Pharmaceuticals plc has a 1 year low of $95.49 and a 1 year high of $148.06. The company has a market cap of $6.90 billion, a price-to-earnings ratio of 15.97, a P/E/G ratio of 1.04 and a beta of 0.42. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Analyst Ratings Changes

A number of brokerages have commented on JAZZ. Needham & Company LLC reiterated a "buy" rating and issued a $210.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, April 10th. Royal Bank of Canada decreased their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating for the company in a report on Wednesday, February 26th. Piper Sandler reaffirmed an "overweight" rating and set a $176.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Wells Fargo & Company raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. Finally, Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and upped their price objective for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $187.71.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 4,813 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total value of $695,093.46. Following the completion of the sale, the chief accounting officer now directly owns 8,237 shares in the company, valued at $1,189,587.54. This represents a 36.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Neena M. Patil sold 3,800 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the transaction, the executive vice president now directly owns 33,318 shares in the company, valued at $4,826,778.66. This trade represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,736 shares of company stock worth $4,023,305. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.